CENT Stock Analysis: Central Garden & Pet | NASDAQ
Packaged Foods | NASDAQ, USA | Market Cap: 2.680m USD | 12M Return: 5.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.63M
EPS Trend: 88.5%
Qual. Beats: 1
Rev. Trend: -88.4%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Central Garden & Pet Company (CENT) is a producer and distributor of branded products for the pet and lawn and garden industries. The company operates through two primary segments: Pet, which offers supplies for domestic animals, aquatics, and livestock; and Garden, which provides seeds, fertilizers, and pest control solutions. Its portfolio includes established brands such as Nylabone, Kaytee, Pennington, and Sevin.
The business model relies on a dual strategy of manufacturing proprietary brands and distributing third-party products to a diverse retail base, including big-box retailers, e-commerce platforms, and independent nurseries. This sector is characterized by relatively stable demand, as pet care and home maintenance are often treated as essential non-discretionary expenses by consumers. The company’s mid-cap valuation reflects its established position within the Consumer Staples sector since its 1993 IPO.
Investors can evaluate the company’s valuation metrics and historical growth trends by exploring the detailed data sets on ValueRay. Central Garden & Pet remains headquartered in Walnut Creek, California, maintaining a focus on the North American retail market.
- Pet segment margins expand through high-value treats and health products
- Garden segment revenue fluctuates based on seasonal weather and planting cycles
- Retail inventory destocking at big-box partners impacts quarterly volume
- Strategic acquisitions and brand consolidation drive long-term capital allocation efficiency
| Net Income: 171.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -1.64 > 1.0 |
| NWC/Revenue: 46.88% < 20% (prev 43.65%; Δ 3.22% < -1%) |
| CFO/TA 0.09 > 3% & CFO 328.3m > Net Income 171.5m |
| Net Debt (974.9m) to EBITDA (367.9m): 2.65 < 3 |
| Current Ratio: 3.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (61.9m) vs 12m ago -4.53% < -2% |
| Gross Margin: 32.21% > 18% (prev 30.00%; Δ 2.21% > 0.5%) |
| Asset Turnover: 85.76% > 50% (prev 86.95%; Δ -1.18% > 0%) |
| Interest Coverage Ratio: 4.96 > 6 (EBIT TTM 284.2m / Interest Expense TTM 57.3m) |
| A: 0.40 (Total Current Assets 2.09b - Total Current Liabilities 605.2m) / Total Assets 3.75b |
| B: 0.29 (Retained Earnings 1.09b / Total Assets 3.75b) |
| C: 0.08 (EBIT TTM 284.2m / Avg Total Assets 3.69b) |
| D: 0.79 (Book Value of Equity 1.65b / Total Liabilities 2.09b) |
| Altman-Z'' = 4.89 = AA |
| DSRI: 1.04 (Receivables 603.2m/578.9m, Revenue 3.16b/3.16b) |
| GMI: 0.93 (GM 30.00% / 32.21%) |
| AQI: 0.99 (AQ_t 0.29 / AQ_t-1 0.30) |
| SGI: 1.00 (Revenue 3.16b / 3.16b) |
| TATA: -0.04 (NI 171.5m - CFO 328.3m) / TA 3.75b) |
| Beneish M = -3.06 (Cap -4..+1) = AA |
As of July 13, 2026, the stock is trading at USD 42.89 with a total of 57,583 shares traded. Over the past week, the price has changed by -2.41%, over one month by +0.09%, over three months by +12.57% and over the past year by +5.88%.
Current recommended Stop Loss: 40.70 (which is 5.1% or 1.8 ATR below the current price).
Central Garden & Pet has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CENT.
- StrongBuy: 3
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 47.5 | 10.7% |
P/E Trailing = 15.5745
P/E Forward = 13.2626
P/S = 0.8474
P/B = 1.6641
P/EG = 2.0079
Revenue TTM = 3.16b USD
EBIT TTM = 284.2m USD
EBITDA TTM = 367.9m USD
Long Term Debt = 1.19b USD (from longTermDebt, last quarter)
Short Term Debt = 51.6m USD (from shortTermDebt, last quarter)
Debt = 1.64b USD (from shortLongTermDebtTotal, last quarter) + Leases 225.9m
Net Debt = 974.9m USD (calculated: Debt 1.64b - CCE 669.4m)
Enterprise Value = 3.65b USD (2.68b + Debt 1.64b - CCE 669.4m)
Interest Coverage Ratio = 4.96 (Ebit TTM 284.2m / Interest Expense TTM 57.3m)
EV/FCF = 12.94x (Enterprise Value 3.65b / FCF TTM 282.4m)
FCF Yield = 7.73% (FCF TTM 282.4m / Enterprise Value 3.65b)
FCF Margin = 8.93% (FCF TTM 282.4m / Revenue TTM 3.16b)
Net Margin = 5.42% (Net Income TTM 171.5m / Revenue TTM 3.16b)
Gross Margin = 32.21% ((Revenue TTM 3.16b - Cost of Revenue TTM 2.14b) / Revenue TTM)
Gross Margin QoQ = 33.06% (prev 30.87%)
Tobins Q-Ratio = 0.98 (Enterprise Value 3.65b / Total Assets 3.75b)
Interest Expense / Debt = 3.48% (Interest Expense 57.3m / Debt 1.64b)
Taxrate = 24.30% (55.1m / 226.9m)
NOPAT = 215.2m (EBIT 284.2m * (1 - 24.30%))
Current Ratio = 3.45 (Total Current Assets 2.09b / Total Current Liabilities 605.2m)
Debt / Equity = 1.00 (Debt 1.64b / totalStockholderEquity, last quarter 1.65b)
Debt / EBITDA = 2.65 (Net Debt 974.9m / EBITDA 367.9m)
Debt / FCF = 3.45 (Net Debt 974.9m / FCF TTM 282.4m)
Total Stockholder Equity = 1.60b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.65% (Net Income 171.5m / Total Assets 3.75b)
RoE = 10.72% (Net Income TTM 171.5m / Total Stockholder Equity 1.60b)
RoCE = 10.18% (EBIT 284.2m / Capital Employed (Equity 1.60b + L.T.Debt 1.19b))
RoIC = 7.09% (NOPAT 215.2m / Invested Capital 3.03b)
WACC = 5.17% (E(2.68b)/V(4.32b) * Re(6.73%) + D(1.64b)/V(4.32b) * Rd(3.48%) * (1-Tc(0.24)))
Discount Rate = 6.73% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -51.11 | Cagr: 6.79%
[DCF] Terminal Value 73.10% ; FCFF base≈302.7m ; Y1≈265.4m ; Y5≈214.5m
[DCF] Fair Price = 255.7 (EV 3.44b - Net Debt 974.9m = Equity 2.47b / Shares 9.65m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 88.46 | EPS CAGR: 12.16% | SUE: 2.23 | # QB: 1
Revenue Correlation: -88.42 | Revenue CAGR: -2.47% | SUE: 2.21 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.51 | Chg30d=-0.66% | Revisions=-25% | Analysts=5
EPS current Year (2026-09-30): EPS=2.97 | Chg30d=-0.34% | Revisions=-25% | GrowthEPS=+8.6% | GrowthRev=-2.7%
EPS next Year (2027-09-30): EPS=3.09 | Chg30d=-0.32% | Revisions=-25% | GrowthEPS=+4.0% | GrowthRev=-3.2%
[Analyst] Revisions Ratio: -50% (up=0, down=3)